Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 120 articles:
HTML format



Single Articles


    June 2024
  1. KATO T, Yang JC, Ahn MJ, Sakai H, et al
    Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Br J Cancer. 2024;130:1679-1686.
    PubMed     Abstract available


    May 2024
  2. YOSHIMURA A, Horinaka M, Yaoi T, Ono H, et al
    Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
    Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727.
    PubMed     Abstract available


  3. MALAPELLE U, Leighl N, Addeo A, Hershkovitz D, et al
    Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02709.
    PubMed     Abstract available


  4. JEONG H, Koh J, Kim S, Song SG, et al
    Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Br J Cancer. 2024 May 10. doi: 10.1038/s41416-024-02698.
    PubMed     Abstract available


    April 2024
  5. LI C, Liu L, You R, Li Y, et al
    Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
    Br J Cancer. 2024 Apr 9. doi: 10.1038/s41416-024-02678.
    PubMed     Abstract available


  6. MATHIESON L, Koppensteiner L, Dorward DA, O'Connor RA, et al
    Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
    Br J Cancer. 2024 Apr 6. doi: 10.1038/s41416-024-02671.
    PubMed     Abstract available


  7. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    PubMed     Abstract available


  8. GORGULHO J, Roderburg C, Beier F, Bokemeyer C, et al
    Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
    Br J Cancer. 2024;130:1013-1022.
    PubMed     Abstract available


  9. KANAHORI M, Shimada E, Matsumoto Y, Endo M, et al
    Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8(+) T cell infiltration.
    Br J Cancer. 2024;130:1083-1095.
    PubMed     Abstract available


    March 2024
  10. HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al
    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662.
    PubMed     Abstract available


  11. FU X, Liu S, Cao D, Li C, et al
    Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
    Br J Cancer. 2024;130:716-727.
    PubMed     Abstract available


  12. BLANCO E, Silva-Pilipich N, Bocanegra A, Chocarro L, et al
    Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
    Br J Cancer. 2024;130:869-879.
    PubMed     Abstract available


    February 2024
  13. BLECHTER B, Wong JYY, Chien LH, Shiraishi K, et al
    Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02592.
    PubMed     Abstract available


  14. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Correction: Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02603.
    PubMed    


  15. FONT A, Mellado B, Climent MA, Virizuela JA, et al
    Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
    Br J Cancer. 2024;130:434-441.
    PubMed     Abstract available


    January 2024
  16. REN Z, Dharmaratne M, Liang H, Benard O, et al
    Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1alpha.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522.
    PubMed     Abstract available


  17. MEZQUITA L, Oulhen M, Aberlenc A, Deloger M, et al
    Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
    Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02535.
    PubMed     Abstract available


  18. LEONETTI A, Verze M, Minari R, Perrone F, et al
    Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
    Br J Cancer. 2024;130:135-142.
    PubMed     Abstract available


    December 2023
  19. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2023 Dec 30. doi: 10.1038/s41416-023-02553.
    PubMed     Abstract available


  20. CHEN B, Yao W, Li X, Lin G, et al
    A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02519.
    PubMed     Abstract available


  21. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    PubMed     Abstract available


  22. THOMPSON JC, Scholes DG, Carpenter EL, Aggarwal C, et al
    Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.
    Br J Cancer. 2023;129:1893-1902.
    PubMed     Abstract available


    November 2023
  23. ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al
    Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
    Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491.
    PubMed     Abstract available


  24. QU FJ, Zhou Y, Wu S
    Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases.
    Br J Cancer. 2023 Nov 9. doi: 10.1038/s41416-023-02482.
    PubMed     Abstract available


  25. HUNTER B, Argyros C, Inglese M, Linton-Reid K, et al
    Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis.
    Br J Cancer. 2023 Nov 6. doi: 10.1038/s41416-023-02480.
    PubMed     Abstract available


  26. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
    Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
    Br J Cancer. 2023 Nov 3. doi: 10.1038/s41416-023-02481.
    PubMed    


  27. TANG M, Burgess JT, Fisher M, Boucher D, et al
    Targeting the COMMD4-H2B protein complex in lung cancer.
    Br J Cancer. 2023 Nov 1. doi: 10.1038/s41416-023-02476.
    PubMed     Abstract available


  28. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    PubMed     Abstract available


    October 2023
  29. JANI BD, Sullivan MK, Hanlon P, Nicholl BI, et al
    Personalised lung cancer risk stratification and lung cancer screening: do general practice electronic medical records have a role?
    Br J Cancer. 2023 Oct 25. doi: 10.1038/s41416-023-02467.
    PubMed     Abstract available


  30. YANG Z, Zhu J, Yang T, Tang W, et al
    Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma.
    Br J Cancer. 2023;129:1397-1408.
    PubMed     Abstract available


  31. SICARD G, Protzenko D, Giacometti S, Barlesi F, et al
    Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
    Br J Cancer. 2023;129:1373-1382.
    PubMed     Abstract available


  32. PARRA ER, Ilie M, Wistuba II, Hofman P, et al
    Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.
    Br J Cancer. 2023;129:1417-1431.
    PubMed     Abstract available


    September 2023
  33. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
    Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
    Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02427.
    PubMed     Abstract available


  34. GASSLER N, Zhang C, Wenger T, Schnabel PA, et al
    Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
    Br J Cancer. 2023 Sep 18. doi: 10.1038/s41416-023-02433.
    PubMed    


  35. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
    Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
    Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
    PubMed     Abstract available


  36. YANG Y, Xu S, Jia G, Yuan F, et al
    Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
    Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
    PubMed     Abstract available


  37. SHARMA S, Tyagi W, Tamang R, Das S, et al
    HDAC5 modulates SATB1 transcriptional activity to promote lung adenocarcinoma.
    Br J Cancer. 2023;129:586-600.
    PubMed     Abstract available


  38. ALMANGUSH A, Makitie AA, Leivo I
    Can TILs supplement the TNM staging system (as TNM-Immune)?
    Br J Cancer. 2023;129:739-740.
    PubMed    


    August 2023
  39. XU M, Tu Y, Bi W, Lundberg MZ, et al
    SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53.
    Br J Cancer. 2023;129:531-540.
    PubMed     Abstract available


    July 2023
  40. STRAUSS MH, Sipahi I, Hall AS
    ACE inhibitors and the risk of lung cancer-is there causality?
    Br J Cancer. 2023 Jul 4. doi: 10.1038/s41416-023-02346.
    PubMed    


  41. MUNRO HM, Yu D, Zheng W, Blot WJ, et al
    Diet quality and lung cancer incidence in a low-income population in the United States.
    Br J Cancer. 2023 Jul 3. doi: 10.1038/s41416-023-02342.
    PubMed     Abstract available


  42. ANGELES AK, Janke F, Daum AK, Reck M, et al
    Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma.
    Br J Cancer. 2023;129:112-121.
    PubMed     Abstract available


    June 2023
  43. XU L, Su H, Zhao S, Si H, et al
    Development of the semi-dry dot-blot method for intraoperative detecting micropapillary component in lung adenocarcinoma based on proteomics analysis.
    Br J Cancer. 2023;128:2116-2125.
    PubMed     Abstract available


    May 2023
  44. GUO JH, Ma YS, Lin JW, Jiang GX, et al
    Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway.
    Br J Cancer. 2023 May 13. doi: 10.1038/s41416-023-02301.
    PubMed     Abstract available


  45. WEN SWC, Nederby L, Andersen RF, Hansen TS, et al
    NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Br J Cancer. 2023 May 3. doi: 10.1038/s41416-023-02285.
    PubMed     Abstract available


  46. AFTAB F, Rodriguez-Fuguet A, Silva L, Kobayashi IS, et al
    An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.
    Br J Cancer. 2023;128:1647-1664.
    PubMed     Abstract available


  47. HEYLEN E, Verstraete P, Van Aerschot L, Geeraerts SL, et al
    Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer.
    Br J Cancer. 2023;128:1862-1878.
    PubMed     Abstract available


    April 2023
  48. CHOI YR, Kang EH, Kim S, Park SY, et al
    Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.
    Br J Cancer. 2023 Apr 14. doi: 10.1038/s41416-023-02264.
    PubMed     Abstract available


  49. MARKHAM JF, Fellowes AP, Green T, Leal JL, et al
    Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.
    Br J Cancer. 2023;128:1148-1154.
    PubMed     Abstract available


  50. JUSTE-LANAS Y, Diaz-Valdivia N, Llorente A, Ikemori R, et al
    3D collagen migration patterns reveal a SMAD3-dependent and TGF-beta1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma.
    Br J Cancer. 2023;128:967-981.
    PubMed     Abstract available


  51. BYUN JK, Lee SH, Moon EJ, Park MH, et al
    Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity.
    Br J Cancer. 2023;128:1491-1502.
    PubMed     Abstract available


  52. XU S, Li X, Geng J, Cao Y, et al
    Sec61gamma is a vital protein in the endoplasmic reticulum membrane promoting tumor metastasis and invasion in lung adenocarcinoma.
    Br J Cancer. 2023;128:1478-1490.
    PubMed     Abstract available


    March 2023
  53. DIAO MN, Zhang XJ, Zhang YF
    The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy.
    Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02246.
    PubMed     Abstract available


  54. VALKO Z, Megyesfalvi Z, Schwendenwein A, Lang C, et al
    Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Br J Cancer. 2023 Mar 14. doi: 10.1038/s41416-023-02219.
    PubMed     Abstract available


  55. ZHANG X, Wang H, Liu W, Xiao Z, et al
    Molecular features and evolutionary trajectory of ASCL1(+) and NEUROD1(+) SCLC cells.
    Br J Cancer. 2023;128:748-759.
    PubMed     Abstract available


  56. GENG Q, Li L, Shen Z, Zheng Y, et al
    Norepinephrine inhibits CD8(+) T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma.
    Br J Cancer. 2023;128:1223-1235.
    PubMed     Abstract available


    February 2023
  57. LUO J, Hendryx M, Dong Y
    Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02177.
    PubMed     Abstract available


  58. LEYDEN GM, Greenwood MP, Gaborieau V, Han Y, et al
    Disentangling the aetiological pathways between body mass index and site-specific cancer risk using tissue-partitioned Mendelian randomisation.
    Br J Cancer. 2023;128:618-625.
    PubMed     Abstract available


  59. GOBERDHAN DCI
    Large tumour-derived extracellular vesicles as prognostic indicators of metastatic cancer patient survival.
    Br J Cancer. 2023;128:471-473.
    PubMed     Abstract available


  60. WORTH KR, Papandreou I, Hammond EM
    How the histological structure of some lung cancers shaped almost 70 years of radiobiology.
    Br J Cancer. 2023;128:407-412.
    PubMed     Abstract available


    January 2023
  61. CHAN CH, Chiou LW, Lee TY, Liu YR, et al
    PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib.
    Br J Cancer. 2023;128:148-159.
    PubMed     Abstract available


  62. CERONE MA, Mills TC, Sharpe R, McBride D, et al
    The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
    Br J Cancer. 2023;128:161-164.
    PubMed     Abstract available


    December 2022
  63. ZHANG X, Yu Z, Xu Y, Chao Y, et al
    Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules.
    Br J Cancer. 2022;127:2154-2165.
    PubMed     Abstract available


    November 2022
  64. WU Z, Yao T, Wang Z, Liu B, et al
    Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02029.
    PubMed     Abstract available


  65. BEHAR HARPAZ S, Weber MF, Wade S, Ngo PJ, et al
    Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.
    Br J Cancer. 2022 Nov 3. pii: 10.1038/s41416-022-02026.
    PubMed     Abstract available


  66. NGUYEN TT, Lee HS, Burt BM, Amos CI, et al
    A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
    Br J Cancer. 2022;127:1691-1700.
    PubMed     Abstract available


  67. HILTBRUNNER S, Fleischmann Z, Sokol ES, Zoche M, et al
    Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Br J Cancer. 2022;127:1997-2005.
    PubMed     Abstract available


    October 2022
  68. MARINELLO J, Arleo A, Russo M, Delcuratolo M, et al
    Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway.
    Br J Cancer. 2022;127:1214-1225.
    PubMed     Abstract available


  69. SARKAR BHATTACHARYA S, Thirusangu P, Jin L, Staub J, et al
    PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM.
    Br J Cancer. 2022;127:1352-1364.
    PubMed     Abstract available


    September 2022
  70. ZULATO E, Del Bianco P, Nardo G, Attili I, et al
    Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2022 Sep 29. pii: 10.1038/s41416-022-01978.
    PubMed     Abstract available


  71. WANG Y, Han H, Zhang F, Lv T, et al
    Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
    Br J Cancer. 2022 Sep 5. pii: 10.1038/s41416-022-01930.
    PubMed    


  72. RIZZO A
    Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.
    Br J Cancer. 2022 Sep 5. pii: 10.1038/s41416-022-01929.
    PubMed    


  73. LI H, Sun Z, Xiao R, Qi Q, et al
    Stepwise evolutionary genomics of early-stage lung adenocarcinoma manifesting as pure, heterogeneous and part-solid ground-glass nodules.
    Br J Cancer. 2022;127:747-756.
    PubMed     Abstract available


  74. GARCIA-PARDO M, Makarem M, Li JJN, Kelly D, et al
    Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
    Br J Cancer. 2022;127:592-602.
    PubMed     Abstract available


  75. ZHANG Y, Liu X, Zeng L, Zhao X, et al
    Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment.
    Br J Cancer. 2022 Sep 1. pii: 10.1038/s41416-022-01956.
    PubMed     Abstract available


  76. WANG Y, Han H, Zhang F, Lv T, et al
    Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
    Br J Cancer. 2022;127:948-956.
    PubMed     Abstract available


    June 2022
  77. LYTHGOE MP, Prasad V
    Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.
    Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01893.
    PubMed     Abstract available


    May 2022
  78. MIN HY, Lee HJ, Suh YA, Pei H, et al
    Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01843.
    PubMed     Abstract available


  79. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available


  80. EDWARDS CJ, Sette A, Cox C, Di Fiore B, et al
    The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
    Br J Cancer. 2022;126:1168-1177.
    PubMed     Abstract available


    April 2022
  81. ZHANG B, Stewart CA, Wang Q, Cardnell RJ, et al
    Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01811.
    PubMed     Abstract available


  82. MURCIANO-GOROFF YR, Pak T, Mondaca S, Flynn JR, et al
    Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers.
    Br J Cancer. 2022;126:889-898.
    PubMed     Abstract available


    March 2022
  83. BONANNO L, Dal Maso A, Pavan A, Zulato E, et al
    Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
    Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01777.
    PubMed     Abstract available


    February 2022
  84. WEI S, Liu W, Xu M, Qin H, et al
    Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer.
    Br J Cancer. 2022 Feb 25. pii: 10.1038/s41416-022-01744.
    PubMed     Abstract available


  85. ZHANG P, Chen PL, Li ZH, Zhang A, et al
    Association of smoking and polygenic risk with the incidence of lung cancer: a prospective cohort study.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01736.
    PubMed     Abstract available


  86. PATEL AJ, Tan TM, Richter AG, Naidu B, et al
    A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.
    Br J Cancer. 2022;126:238-246.
    PubMed     Abstract available


    November 2021
  87. TAMMINGA M, Andree KC, van den Bos H, Hiltermann TJN, et al
    Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Br J Cancer. 2021 Nov 30. pii: 10.1038/s41416-021-01634.
    PubMed     Abstract available


  88. CAMINA N, Penning TM
    Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer.
    Br J Cancer. 2021 Nov 29. pii: 10.1038/s41416-021-01642.
    PubMed     Abstract available


  89. ALIAGAS E, Alay A, Martinez-Iniesta M, Hernandez-Madrigal M, et al
    Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Br J Cancer. 2021;125:1365-1376.
    PubMed     Abstract available


  90. GARINET S, Didelot A, Denize T, Perrier A, et al
    Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC.
    Br J Cancer. 2021;125:1544-1551.
    PubMed     Abstract available


    October 2021
  91. BALL S, Hyde C, Hamilton W, Bright CJ, et al
    An evaluation of a national mass media campaign to raise public awareness of possible lung cancer symptoms in England in 2016 and 2017.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01573.
    PubMed     Abstract available


  92. HOPKINS AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, et al
    Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Br J Cancer. 2021 Oct 28. pii: 10.1038/s41416-021-01606.
    PubMed     Abstract available


  93. MARTINEZ-MARTI A, Felip E, Mancuso FM, Caratu G, et al
    Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
    Br J Cancer. 2021 Oct 1. pii: 10.1038/s41416-021-01558.
    PubMed     Abstract available


    September 2021
  94. LINDSAY CR, Shaw EC, Moore DA, Rassl D, et al
    Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
    Br J Cancer. 2021 Sep 6. pii: 10.1038/s41416-021-01407.
    PubMed     Abstract available


    August 2021
  95. ROSELL R, Cardona AF, Arrieta O, Aguilar A, et al
    Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01519.
    PubMed     Abstract available


  96. NI Y, Peng J, Yang X, Wei Z, et al
    Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer.
    Br J Cancer. 2021;125:672-678.
    PubMed     Abstract available


  97. LAPIDOT M, Case AE, Weisberg EL, Meng C, et al
    Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
    Br J Cancer. 2021;125:582-592.
    PubMed     Abstract available


  98. JORDAN AM
    Molecularly profiled trials: toward a framework of actions for the "nil actionables".
    Br J Cancer. 2021;125:473-478.
    PubMed     Abstract available


    July 2021
  99. SUI Y, Hu W, Zhang W, Li D, et al
    Insights into homeobox B9: a propeller for metastasis in dormant prostate cancer progenitor cells.
    Br J Cancer. 2021 Jul 10. pii: 10.1038/s41416-021-01482.
    PubMed     Abstract available


  100. MU W, Katsoulakis E, Whelan CJ, Gage KL, et al
    Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2021;125:229-239.
    PubMed     Abstract available


  101. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
    CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
    Br J Cancer. 2021;125:176-189.
    PubMed     Abstract available


  102. GUO L, Kaumaya PTP
    First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.
    Br J Cancer. 2021;125:152-154.
    PubMed     Abstract available


    June 2021
  103. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available


    May 2021
  104. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01439.
    PubMed    


  105. CHENG Y, Wang Q, Li K, Shi J, et al
    Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01356.
    PubMed     Abstract available


  106. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 May 17. pii: 10.1038/s41416-021-01436.
    PubMed    


  107. ROUND T, L'Esperance V, Bayly J, Brain K, et al
    COVID-19 and the multidisciplinary care of patients with lung cancer: an evidence-based review and commentary.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01361.
    PubMed     Abstract available


  108. LIN JJ, Gainor JF
    An early look at selective RET inhibitor resistance: new challenges and opportunities.
    Br J Cancer. 2021;124:1757-1758.
    PubMed     Abstract available


  109. LARIJANI B, Miles J, Ward SG, Parker PJ, et al
    Quantification of biomarker functionality predicts patient outcomes.
    Br J Cancer. 2021;124:1618-1620.
    PubMed     Abstract available


    April 2021
  110. ROBBINS HA, Alcala K, Swerdlow AJ, Schoemaker MJ, et al
    Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01278.
    PubMed     Abstract available


    March 2021
  111. YANG H, Hall SRR, Sun B, Yao F, et al
    Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1177-1178.
    PubMed    


  112. WHITE MG, Eng OS
    Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
    Br J Cancer. 2021;124:1179-1180.
    PubMed    


  113. JIA L, Ge X, Du C, Chen L, et al
    EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-beta/SMAD signalling.
    Br J Cancer. 2021;124:1301-1311.
    PubMed     Abstract available


  114. SHIRASAWA M, Yoshida T, Horinouchi H, Kitano S, et al
    Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
    Br J Cancer. 2021;124:925-932.
    PubMed     Abstract available


    February 2021
  115. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


  116. WHITE MG, Schulte JJ, Xue L, Berger Y, et al
    Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
    Br J Cancer. 2021;124:564-566.
    PubMed     Abstract available


    January 2021
  117. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available


  118. SUGANO T, Masuda M, Takeshita F, Motoi N, et al
    Pharmacological blockage of transforming growth factor-beta signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846.
    Br J Cancer. 2021;124:228-236.
    PubMed     Abstract available


  119. BAE K, Kim JH, Jung H, Kong SY, et al
    A fusion of CD63-BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis.
    Br J Cancer. 2021;124:290-298.
    PubMed     Abstract available


    December 2020
  120. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.